Ouro Medicines Raises $120 Million to Develop Immune Reset Therapeutics

Biotech startup Ouro Medicines secures substantial funding to develop immune reset therapeutics for chronic immune-mediated conditions.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here